nadis glp-1 and NAD+ Users have emphasized realistic expectations nadis glp-1 GLP-1 receptor agonists

Confirm prior authorization requirements and formulary coverage before starting treatment

MFP as a De Facto LOE For drugs already in the Medicare negotiation pool, the MFP implementation date functions commercially as a secondary LOE

Phosphodiesterase-5 (PDE5) inhibitors such as sildenafil are often effective first-line treatments and are generally safe to use alongside GLP-1 medications, though they are contraindicated with nitrate medications and riociguat, and should be used with caution in unstable cardiovascular disease or if taking alpha-blockers

Some patients benefit from the Precision Peptide Genetic Test ($99 add-on), which identifies individual variations in GLP-1 receptor, GIP receptor, and metabolic genes that predict medication response

In contrast, switching among patients with an active supply of AOM semaglutide declined slightly from June to July 2025 (1.9%) compared to an average switching rate of 2.3% from January to April

If you share your feelings or ask a question, they will follow up with questions or provide helpful resources or suggestions